Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1602 (ubrogepant) for Acute Migraine Treatment
NCT01657370Phase 2Completed
- Sponsor
- Allergan
- Start
- Aug 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ubrogepant in migraine (6 arms), sponsored by Allergan. Primary endpoints: Dry Blood Spot MK-1602 Concentration at 2 hours, Pain Freedom at 2 hours and 1 more. Started Aug 2012; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01657370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01657370.